SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-226110
Filing Date
2022-08-22
Accepted
2022-08-22 09:22:03
Documents
14
Period of Report
2022-08-22
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d399465d8k.htm   iXBRL 8-K 41713
2 EX-3.1 d399465dex31.htm EX-3.1 7398
3 EX-3.2 d399465dex32.htm EX-3.2 46939
  Complete submission text file 0001193125-22-226110.txt   241187

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20220822.xsd EX-101.SCH 2899
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20220822_lab.xml EX-101.LAB 18740
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20220822_pre.xml EX-101.PRE 11736
8 EXTRACTED XBRL INSTANCE DOCUMENT d399465d8k_htm.xml XML 3655
Mailing Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451
Business Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 617-715-3600
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36282 | Film No.: 221182402
SIC: 2836 Biological Products, (No Diagnostic Substances)